Biohaven says opakalim triples median time to second seizure day in idiopathic generalized epilepsy trial

Biohaven

Biohaven

BHVN

0.00
  • Biohaven flagged new clinical data for epilepsy drug opakalim, with additional updates set for presentation at its R&D Day on May 27, 2026.
  • A small controlled study in idiopathic generalized epilepsy showed a clear signal of improved seizure control versus placebo.
  • An ongoing open-label study in refractory focal epilepsy showed many patients sustained meaningful reductions in seizure frequency over extended treatment.
  • A compassionate-use case in a child with KCNQ2-related epilepsy indicated continued clinical stability with ongoing seizure control.
  • Biohaven reiterated plans for top-line results in 2H 2026 from the first of two pivotal Phase 2/3 studies in refractory focal epilepsy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biohaven Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605260730PR_NEWS_USPR_____NE67410) on May 26, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.